Drugs / NENDOCABTAGENE ONOGEDLEUCEL
NENDOCABTAGENE ONOGEDLEUCEL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04093596 | Sep 2019 → Jan 2025 | refractory plasma cell neoplasm | Allogene Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NENDOCABTAGENE ONOGEDLEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068149 ↗ |
| Known as | ALLO-715 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093596 ↗ |
| Known as | Nendocabtagen onogedleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068149 ↗ |
| Known as | Nendocabtagene onogedleucel (inn) | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068149 ↗ |
| Modality | Cell therapy | “ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA” NCT04093596 ↗ |